Skip to main content

Clinical Trials Using Fludarabine Phosphate

Review the clinical trials studying fludarabine phosphate on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 51

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Status: Active
Location: 23 locations
Venetoclax in Combination with Conventional Chemotherapy for the Treatment of Pediatric Patients with Acute Myeloid Leukemia
Status: Active
Location: 9 locations
Cytokine Induced Memory-Like Natural Killer Cells Combined with Atezolizumab for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Location: 7 locations
GD2CART for the Treatment of H3K27M Mutated Diffuse Intrinsic Pontine Glioma or Spinal Diffuse Midline Glioma
Status: Active
Location: 2 locations
Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies
Status: Active
Location: 2 locations
UF-KURE19 CAR-T Cells for Treatment of Non-Hodgkin Lymphomas
Status: Active
Location: 3 locations
T Cells (EAGD T-Cells) after Stem Cell Transplantation and Post-transplant Cyclophosphamide for the Treatment of Blood Cancers
Status: Active
Location: 2 locations
Genetically Modified Donor Stem Cell Transplant Followed by Zoledronic Acid in Treating Younger Patients with Relapsed/Refractory Hematologic Malignancies or High Risk Solid Tumors
Status: Active
Location: 2 locations
Cytokine Induced Memory-Like Natural Killer Cells in Combination with Aldesleukin for the Treatment of Locally Advanced or Metastatic Renal Cell Cancer or Urothelial Cancer
Status: Active
Location: 2 locations
A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia, INFLUENCE Trial
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Venetoclax with Busulfan, Thiotepa, Cladribine, and Fludarabine for the Treatment of High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Cell Therapy for the Treatment of Locally Advanced, Metastatic, or Recurrent Solid Cancers
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients with Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Total Marrow and Lymphoid Irradiation as Conditioning Regimen before Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome or Acute Leukemia
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Donor Stem Cell Transplant with Treosulfan, Fludarabine, and Thiotepa in Treating Patients with Non-malignant Disorders
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Chemotherapy and Cord Blood Transplant in Children and Young Adults with Blood Cancers or Non-malignant Disorders
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Genetically Engineered Cells (ATLCAR.CD30 T Cells) for the Treatment of Relapsed or Refractory CD30 Positive Peripheral T Cell Lymphoma
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Optimized Cord Blood Transplant with Intermediate Intensity Conditioning Regimen for the Treatment of Relapsed High-Risk Hematologic Cancers after First Donor Stem Cell Transplant
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Personalized NK Cell Therapy after Chemotherapy and Cord Blood Transplant in Treating Patients with Myelodysplastic Syndrome, Leukemia, Lymphoma or Multiple Myeloma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients with High-Risk Hematologic Diseases
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Anti-Thymocyte Globulin added to Tacrolimus and Methotrexate for Reducing Graft Versus Host Disease after Hematopoietic Stem Cell Transplant for Hematologic Cancers
Status: Active
Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
211^At-BC8-B10 before Donor Stem Cell Transplant in Treating Patients with High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
211At-BC8-B10 followed by Donor Stem Cell Transplant in Treating Patients with Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington